Global Life Science Business Partnering (GLSBP)

Highlights of September 2022

Lupin, DKSH sign agreement to commercialize five biosimilar candidates in Philippines.
Dr. Reddy’s Labs partners with IQVIA.
Torrent Pharma acquires cosmetic derma player Curatio for Rs 2,000 Crores.
Zydus Lifesciences Ltd. announced that it has acquired the rights to sell MonoFerric in India and Nepal from Pharmacosmos A/S based in Denmark.
Serum Institute signs deal with Aspen to sell vaccines in Africa.
CytoReason and Pfizer ink $110 million AI deal.
Merck inks deal with Sinopharm to commercialize COVID-19 pills in China.
SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals.
Inventiva out-licenses NASH candidate in Greater China.
Hansoh Pharma pays for Chinese rights to KiOmed’s knee osteoarthritis treatment.
Nacuity inks licensing deal with Arctic for HCCAA therapy NPI-001 in Iceland.
Selexis and NexImmune expand long-standing research collaboration.
SpringWorks and GSK expand multiple myeloma collaboration.
Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders.

Updates at Aagami:

Aagami to attend Bio-Japan 2022 (October 11-14) Digitally with more than 20 meetings already scheduled.
Client appreciated Aagami in their press release, for the strategic advisory support given to establish cross-border licensing partnership for their smoking cessation drug.
Aagami to attend BIO-Europe® 2022 (October 24–26 | Leipzig, Germany)
Aagami VP to participate in “Global Bio & Pharma Plaza 2022”. This exhibition will be held from Oct 12th to 13th, 2022 in Seoul, South Korea and focused on the pharmaceuticals and bio-medical sector.

INFOCUS: Select opportunities available at Aagami:

For Partnering/Licensing/ Investment:

Technology Licensing: Easy to apply Microneedle Array Patch (MAP) system to deliver drugs, vaccines; better immune response than injection. A painless and efficient replacement to Syringes.
Investment / Licensing - US FDA approved portable MRI Guided Treatment, Diagnosis and Screening ($40 Million Series C Open). For Urology applications.
Series B Open- Novel Evolution of Portable MRI and Robotics for Neurology treatments like Strokes and TBI.
Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding/licensing/co-development partnerships.

For Acquisition:

Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.